Comparison
Bromantane vs DHEA
Side-by-side of Bromantane and DHEA. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Bromantane
Bromantane, the Russian nootropic sold as Ladasten (ADK-709), acts on dopamine to cut fatigue and anxiety without classical stimulant rebound.
DHEA
DHEA supplement profile: adrenal androgen precursor, typical 25-50 mg dose, DHEA-S targets, evidence for adrenal insufficiency and vaginal atrophy, side effec.
Effects at a glance
Bromantane
- •Russian RCT base (Voznesenskaya 2010, n=728) supports 50 mg daily for asthenia and fatigue over 4 weeks
- •Atypical actogenic mechanism: induces tyrosine hydroxylase rather than direct monoamine release
- •Subjective profile is anxiolytic plus mildly motivating, distinct from classical stimulants
- •Long half-life of around 11 hours supports once-daily morning dosing
- •WADA-banned since 1996; relevant for tested athletes
- •Western evidence base is thin; most published trials are Russian-language and not independently replicated
DHEA
- •Adrenal androgen precursor; serum DHEA-S declines progressively after the third decade of life
- •OTC dietary supplement in US under DSHEA 1994; prescription in EU, UK, Canada, Australia
- •FDA approved as Intrarosa (6.5 mg vaginal insert) for postmenopausal dyspareunia in 2016
- •Acts as tissue-specific prohormone converted intracrinologically to testosterone and estrogens
- •Best evidence: adrenal insufficiency replacement and vaginal atrophy; weaker on cognition and longevity
- •WADA banned in competitive sport; banned in NCAA, MLB, NFL, IOC settings
Side-by-side
| Attribute | Bromantane | DHEA |
|---|---|---|
| Category | nootropic | hormone |
| Also known as | Ladasten, ADK-709, N-(4-bromophenyl)adamantan-2-amine | dehydroepiandrosterone, prasterone, Intrarosa |
| Half-life (hr) ↗ | 11 | 12 |
| Typical dose (mg) ↗ | 75 | 25 |
| Dosing frequency | daily, morning | daily, typically morning |
| Routes | oral | oral, vaginal, topical |
| Onset (hr) | 3 | 1 |
| Peak (hr) | 168 | 1 |
| Molecular weight | 280.21 | 288.42 |
| Molecular formula | C16H20BrN | C19H28O2 |
| Mechanism | Indirect dopaminergic and serotonergic actogenic activity via induction of tyrosine hydroxylase and selective increases in serotonin synthesis in hippocampus and hypothalamus. | Steroid prohormone converted intracrinologically to testosterone and estrogens in target tissues; also exerts direct effects via sigma-1 receptor, GABA-A modulation, and glucocorticoid receptor interaction. |
| Legal status | Approved in Russia (Ladasten); unscheduled and unapproved in US, EU, UK | OTC supplement in US (DSHEA 1994); prescription in EU, UK, Canada, Australia |
| WADA status | banned | banned |
| DEA / Rx | Not scheduled in the US | OTC supplement in US (not scheduled); Rx in EU, UK, Canada, Australia |
| Pregnancy | Not recommended | Contraindicated in pregnancy |
| CAS | 87913-26-6 | 53-43-0 |
| PubChem CID | 9576456 | 5881 |
| Wikidata | Q4093816 | Q411733 |
Safety profile
Bromantane
Common side effects
- mild GI upset
- headache
- skin rash
- occasional insomnia at higher doses
Contraindications
- pregnancy
- lactation
- severe hepatic impairment
- severe renal impairment
- pediatric use
Interactions
- MAOIs: theoretical additive dopaminergic and serotonergic activity(major)
- levodopa and dopamine agonists: additive dopaminergic activity(moderate)
- SSRIs and other serotonergic drugs: theoretical serotonergic additivity(moderate)
- classical stimulants: theoretical additive activity, undocumented(moderate)
DHEA
Common side effects
- acne
- oily skin
- hirsutism (women)
- gynecomastia (men, higher doses)
- irritability
- insomnia
Contraindications
- hormone-sensitive cancer (breast, ovarian, prostate)
- active liver disease
- uncontrolled lipid disorder
- pregnancy and lactation
Interactions
- warfarin: case reports of altered INR; monitor(moderate)
- estrogens (HRT): additive estrogenic effect via conversion; monitor(moderate)
- insulin: may improve insulin sensitivity slightly; monitor glucose(minor)
- anastrozole: may reduce DHEA-derived estrogen; clinical relevance unclear(minor)
Which Should You Take?
DHEA comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Bromantane is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Bromantane.
- → If your priority is fatigue resistance, pick Bromantane.
- → If your priority is hormonal optimization, pick DHEA.
- → If your priority is healthspan extension, pick DHEA.
Edge case: If you want to avoid controlled substance, DHEA is the more accessible choice.
Default choice: DHEA. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Bromantane only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Bromantane and DHEA?
Bromantane and DHEA differ in category (nootropic vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Bromantane or DHEA?
Bromantane half-life is 11 hours; DHEA half-life is 12 hours.
Can you stack Bromantane with DHEA?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper